Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408320 | 0.90 | MTNR1B (0.45) | MTNR1BSIGMAR1SLC6A9KCNH2SLC6A5 | |
| SCHEMBL6406522 | 0.82 | MTNR1B (0.49) | MTNR1BMTNR1A | |
| SCHEMBL6406051 | 0.74 | MTNR1B (0.47) | MTNR1BSLC6A5MTNR1A | |
| SCHEMBL5871250 | 0.73 | MTNR1B (0.64) | MTNR1BSIGMAR1MTNR1A | |
| SCHEMBL8655525 | 0.72 | MTNR1B (0.53) | MTNR1BSIGMAR1SLC6A9KCNH2HRH3 | |
| SCHEMBL22411105 | 0.71 | MAOA (0.47) | MTNR1BSIGMAR1KCNH2SLC6A5HRH3 | |
| SCHEMBL8652211 | 0.70 | MTNR1B (0.52) | MTNR1BSIGMAR1MTNR1A | |
| SCHEMBL8649531 | 0.70 | MTNR1B (0.52) | MTNR1BSIGMAR1SLC6A9KCNH2MTNR1A | |
| SCHEMBL6405994 | 0.69 | GRIN1 (0.45) | MTNR1BSIGMAR1HRH3CYP2D6 | |
| SCHEMBL6408435 | 0.68 | ADRA1D (0.41) | MTNR1BSIGMAR1SLC6A9KCNH2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005113527-A1 | TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | MTNR1B 63/4885SIGMAR1 91/4885SLC6A9 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.